Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Franziska Michor named recipient of NYSCF - Robertson Stem Cell Prize

Franziska Michor named recipient of NYSCF - Robertson Stem Cell Prize

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

CWRU investigator receives $2.82 million NIH grant to make stealth bombs for brain cancer treatment

CWRU investigator receives $2.82 million NIH grant to make stealth bombs for brain cancer treatment

FDA awards research grants to boost product development for patients with rare diseases

FDA awards research grants to boost product development for patients with rare diseases

FDA approves expanded indication for Optune device for brain cancer patients

FDA approves expanded indication for Optune device for brain cancer patients

Scientists map EGFRvIII mutant that causes brain cancer

Scientists map EGFRvIII mutant that causes brain cancer

Rabbit virus can be paired with existing drug to deliver more potent punch to brain tumor cells

Rabbit virus can be paired with existing drug to deliver more potent punch to brain tumor cells

Researchers discover five new genetic variants associated with brain cancer

Researchers discover five new genetic variants associated with brain cancer

Multicenter study shows Monteris’ NeuroBlate System improves outcome in brain tumor patients

Multicenter study shows Monteris’ NeuroBlate System improves outcome in brain tumor patients

Innovative way may stop spread of glioblastoma multiforme

Innovative way may stop spread of glioblastoma multiforme

DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

Innovative vaccine therapy shows promise against glioblastoma brain tumors

Innovative vaccine therapy shows promise against glioblastoma brain tumors

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

UCLA scientists develop promising new combination treatment for glioblastoma

UCLA scientists develop promising new combination treatment for glioblastoma

Northwestern University receives $11.7 million NCI grant to use nanotechnology for cancer treatments

Northwestern University receives $11.7 million NCI grant to use nanotechnology for cancer treatments

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Special issue of Future Science OA highlights research on protein misfolding diseases

Special issue of Future Science OA highlights research on protein misfolding diseases

Tocagen's Toca 511 & Toca FC receives FDA orphan drug designation for treatment of glioblastoma

Tocagen's Toca 511 & Toca FC receives FDA orphan drug designation for treatment of glioblastoma

NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

DelMar closes on $2.6 million registered direct placement

DelMar closes on $2.6 million registered direct placement

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.